Some studies have shown that lower levels of CMG2 correlate with more aggressive soft tissue sarcoma and breast cancer, while others show that higher levels of CMG2 result in poor survival in patients with gastric cancer and glioblastoma [58]. This evidence concerns the gene ANTXR2 and gastric cancer.